CLAIMS:

1. An immunogenic composition comprising unconjugated *Streptococcus pneumoniae* pneumolysin and unconjugated *Streptococcus pneumoniae* PhtD; ~~comprising at least one unconjugated *Streptococcus pneumoniae* protein selected from: pneumolysin and member(s) of the Polyhistidine Triad family;~~ and an adjuvant comprising 25-75μg QS21, 25-75μg monophosphoryl lipid A (MPL), dioleoylphosphatidylcholine (DOPC) and sterol, presented in the form of a liposome.

2. An immunogenic composition as defined in claim 1 wherein the ratio of *Streptococcus pneumoniae* protein: monophosphoryl lipid A (MPL) is 0.05:1 to 3:1 (w/w).

3. An immunogenic composition as defined in claims 1-2 wherein the ratio of *Streptococcus pneumoniae* protein:QS21 is 0.05:1 to 3:1 (w/w).

4. An immunogenic composition as defined in claims 1-3 comprising 5 to 60, 45 to 55, 5 to 20, or 20 to 30 μg (e.g. 20, 25, 30, 35, 40, 45 or 50 μg) monophosphoryl lipid A (MPL).

5. An immunogenic composition as defined in claims 1-4 comprising 5 to 60, 45 to 55, 5 to 20, or 20 to 30 μg (e.g. 20, 25, 30, 35, 40, 45 or 50 μg) QS21.

6. An immunogenic composition as defined in claims 1-5 comprising 0.1 to 10mg, 0.2 to 7, 0.3 to 5, 0.4 to 2, or 0.5 to 1 mg (e.g. 0.4 to 0.6, 0.9 to 1.1, 0.5 or 1 mg) phospholipid.

7. An immunogenic composition as defined in claims 1-6 comprising 0.025 to 2.5, 0.05 to 1.5, 0.075 to 0.75, 0.1 to 0.3, or 0.125 to 0.25 mg (e.g. 0.2 to 0.3, 0.1 to 0.15, 0.25 or 0.125 mg) sterol.

8. An immunogenic composition as defined in claims 1-7 capable of stimulating IL-17 production.

9. The immunogenic composition as defined in claims 1-8 comprising 3 to 90, 3 to 20, 20 to 40 or 40 to 70 μg (e.g. 10, 30 or 60 μg) unconjugated pneumococcal pneumolysin, per human dose.

10. The immunogenic composition as defined in claims 1-9 comprising 3 to 90, 3 to 20, 20 to 40 or 40 to 70 µg (e.g. 10, 30 or 60 µg) unconjugated PhtD, per human dose.

11. An immunogenic composition as defined in claims 1-10 comprising one or more *S. pneumoniae* capsular saccharides.

12. An immunogenic composition as defined in any of the preceding claims wherein the dose volume is between 0.4 and 1.5 ml

13. A vaccine comprising the immunogenic composition as defined in claims 1-12.

14. Use of an immunogenic composition as defined in any one of claims 1-12 in the manufacture of a medicament for treating or preventing a disease caused by *Streptococcus pneumoniae* infection wherein said medicament is to be administered to a patient suffering from or susceptible to *Streptococcus pneumoniae* infection.

15. An immunogenic composition as defined in any one of claims 1-12 for use in treating or preventing a disease caused by *Streptococcus pneumoniae* infection.

16. An immunogenic composition as defined in any one of claims 1 to 12 for use in treating or preventing a disease caused by *Streptococcus pneumoniae* wherein the disease caused by *Streptococcus pneumoniae* infection is pneumonia or invasive pneumococcal disease.

17. Use of an immunogenic composition as defined in any one of claims 1 to 12 in the manufacture of a medicament for use in treating or preventing disease caused by *Streptococcus pneumoniae* wherein the disease caused by *Streptococcus pneumoniae* infection is pneumonia or invasive pneumococcal disease.